Dopamine Transporter and Reward Anticipation in a Dimensional Perspective : A Multimodal Brain Imaging Study by Dubol, Manon et al.
Dopamine Transporter and Reward Anticipation in a Dimensional Perspective: A Multimodal Brain 
Imaging Study 
Manon Dubol1, Christian Trichard1,2, Claire Leroy1,3, Anca-Larisa Sandu1,4, Mehdi Rahim5, Bernard 
Granger1,6,Eleni T Tzavara1,6,7, Laurent Karila1,8, Jean-Luc Martinot1 and Eric Artiges*,1,9 
1 INSERM, Research Unit 1000 ‘Neuroimaging and Psychiatry’, Paris Sud University—Paris Saclay 
University, Paris Descartes University, Maison de Solenn, Paris & Service Hospitalier Frédéric Joliot, 
Orsay, France;  
2 EPS Barthelemy Durand, Etampes, France; 
3 Laboratoire Imagerie Moléculaire In Vivo (IMIV), CEA, INSERM, CNRS, Paris Sud University—Paris 
Saclay University, Orsay, France;  
4 Aberdeen Biomedical Imaging Centre, University of Aberdeen, Foresterhill, Aberdeen, UK;  
5 Parietal Project Team—INRIA, CEA, Neurospin, Gif-Sur-Yvette, France;  
6 Tarnier Psychiatry Department, AP-HP, Cochin Hospital, Paris, France;  
7 INSERM U1130 Research Unit, CNRS UMR 8246, UPMC UM CR18, Paris, France; 
8 AP-HP, Addiction Research and Treatment Center, Paul Brousse Hospital, Villejuif, France;  
9 Groupe Hospitalier Nord Essonne, Psychiatry Department, Orsay, France 
Dopamine function and reward processing are highly interrelated and involve common brain regions 
afferent to the nucleus accumbens, within the mesolimbic pathway. Although dopamine function 
and reward system neural activity are impaired in most psychiatric disorders, it is unknown whether 
alterations in the dopamine system underlie variations in reward processing across a continuum 
encompassing health and these disorders. We explored the relationship between dopamine function 
and neural activity during reward anticipation in 27 participants including healthy volunteers and 
psychiatric patients with schizophrenia, depression, or cocaine addiction, using functional magnetic 
resonance imaging (fMRI) and positron emission tomography (PET) multimodal imaging with a voxel-
based statistical approach. Dopamine transporter (DAT) availability was assessed with PET and 
[11C]PE2I as a marker of presynaptic dopamine function, and reward related neural response was 
assessed using fMRI with a modified Monetary Incentive Delay task. Across all the participants, DAT 
availability in the midbrain correlated positively with the neural response to anticipation of reward 
in the nucleus accumbens. Moreover, this relationship was conserved in each clinical subgroup, 
despite the heterogeneity of mental illnesses examined. For the first time, a direct link between DAT 
availability and reward anticipation was detected within the mesolimbic pathway in healthy and 
psychiatric participants, and suggests that dopaminergic dysfunction is a common mechanism 
underlying the alterations of reward processing observed in patients across diagnostic categories. 
The findings support the use of a dimensional approach in psychiatry, as promoted by the Research 
Domain Criteria project to identify neurobiological signatures of core dysfunctions underling mental 
illnesses. 
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Regional dysfunctions of the dopamine (DA) system and reward-related neural activity have both 
been reported in various psychiatric disorders (Davis et al, 1991; Chau et al, 2004; Hommer et al, 
2011; Fusar-Poli and Meyer-Lindenberg, 2013). Although animal studies have established a close 
relationship between DA and reward using neurophysiological paradigms (Schultz, 1997; Carelli and 
Wightman, 2004), direct evidence for their covariation in humans remains limited. Particularly, it is 
unknown whether gradual alterations in the DA system underlie variations in reward processing 
across a continuum encompassing health and psychiatric disorders. 
 In healthy subjects, positron emission tomography (PET) and functional magnetic resonance imaging 
(fMRI) have been recently used to explore the relationship between DA release and reward-related 
functional activity. Weiland et al (2014, 2016) described positive correlations between DA release 
within the nucleus accumbens (NAcc), assessed with [11C]raclopride, and reward-related activations 
in the prefrontal cortex and NAcc. Similarly, another team showed significant positive correlations 
between DA release in the NAcc and both midbrain and NAcc activations during reward anticipation 
(Schott et al, 2008). The local correlation between DA release and neural activity during anticipation 
of reward in the NAcc has also been observed using PET and [18F]fallypride (Buckholtz et al, 2010). 
Otherwise, using PET and [18F]-FDOPA, correlations between dopamine synthesis capacity within the 
midbrain and reward anticipation and feedback in the prefrontal cortex were also reported (Dreher 
et al, 2008). Thus, PET–fMRI multimodal imaging seems appropriate to assess the relationship 
between the DA system and the reward system from healthy to pathological conditions. 
Abnormalities of the reward system and the mesolimbic DA system have been reported separately in 
patients with psychiatric disorders, including schizophrenia, depression, and addictions (Chau et al, 
2004). Striatal presynaptic DA hyperactivity (Fusar-Poli and Meyer-Lindenberg, 2013) is central to 
the DA hypotheses of schizophrenia (Davis et al, 1991; Kapur, 2003). It has been proposed that DA 
hyperactivity in schizophrenia patients would result in an aberrant attribution of salience to 
irrelevant stimuli (Kapur, 2003), then contributing to abnormal association with reward. In major 
depressive disorder, a reduced striatal response to rewards (Whitton et al, 2015) has been 
hypothesized to relate to the loss of pleasure and motivation found in these patients (Naranjo et al, 
2001). Moreover, the monoamine deficiency hypothesis posits that depressive symptoms arise from 
insufficient levels of serotonin, norepinephrine, but also DA (Delgado, 2006). In addicted patients, 
the magnitude of striatal DA release following drug intake is predictive of the subjective effects of 
the drug (Malison et al, 1995; Volkow et al, 1997). Volkow et al (2011) also highlighted the 
involvement of striatal DA in drug craving in cocaine-dependent subjects. Further, chronic drug users 
display a downregulation of DA and reward systems, attested by lower D2 availability and reward-
related activations (Hommer et al, 2011). 
Among markers of the DA system, the dopamine transporter (DAT), which has a key role in synaptic 
DA regulation, has been proposed to reflect DA system integrity and function (McHugh and Buckley, 
2015). Moreover, though controversial, DAT modifications have been reported in addictions (Volkow 
et al, 2004; Narendran and Martinez, 2008; Leroy et al, 2012; Hirth et al, 2016), mood disorders 
(Pinsonneault et al, 2011), and schizophrenia (Sjoholm et al, 2004; Arakawa et al, 2009; Artiges et al, 
2017). Thus, assessing DAT availability to explore the relationship between DA and reward 
processing in psychiatric populations appears particularly relevant. 
In regard to the assessment of the reward system, the Monetary Incentive Delay (MID) task (Knutson 
et al, 2000) has emerged as the most reliable and the most widely used tool to measure activations 
related to reward anticipation and feedback in fMRI. Indeed, the MID task revealed that anticipation 
of increasing amounts of monetary reward is related to NAcc activation (Knutson et al, 2001a), 
whereas reward feedback is associated with activations within the ventromedial frontal cortex 
(Knutson et al, 2001b). Furthermore, abnormalities of the reward system activity have been 
reported in patients with addiction, schizophrenia and major depression using the MID task (Hagele 
et al, 2015). 
With the establishment of the Research Domain Criteria project (RDoC), the National Institute of 
Mental Health (NIMH) promotes the use of a dimensional approach that can be applied across 
diagnostic boundaries to identify neurobiological signatures of core dysfunctions underling mental 
illnesses (Insel et al, 2010; Hagele et al, 2015). Thus, measuring DA and reward systems in this 
context might clarify the complex relationships between DA at the molecular scale and DA-related 
functional responses across clinical conditions.  
In line with this dimensional approach, we hypothesized that DAT availability would correlate with 
reward anticipation-related neural response in a group of participants including healthy controls and 
patients with schizophrenia, depression, or cocaine-dependence. We assumed that DA and reward 
systems remain strongly associated in psychiatric patients so that abnormal DA function should be 
related to abnormal reward processing. To this end, we used [11C]PE2I PET that assesses DAT 
availability, and fMRI with a modified version of the MID task that assesses reward processing, in 
voxel-based correlational analyses. In addition to the dimensional approach, we examined the 
relationship between DAT and reward-related fMRI activations within each clinical subgroup, in a 
secondary exploratory analysis. 
 
MATERIALS AND METHODS 
PET and fMRI investigations were approved by the regional biomedical research ethics committee 
(CPP Ile de France 7), and each participant gave written informed consent after receiving full 
information on the procedures. 
Participants 
In this study, we used PET images acquired with [11C]PE2I in healthy and psychiatric samples, on 
which previous PET studies investigating DAT were based (Leroy et al, 2012; Karila et al, 2016; 
Artiges et al, 2017). From this database, twenty-seven participants were selected based on the 
combined presence of PET images and fMRI data acquired with the MID task, that passed quality 
control (Supplementary Figure S1). Our sample included six healthy controls (HC); ten cocaine-
dependent patients that were abstinent for at least 3 days (COC); six patients with schizophrenia 
(SCZ) and five depressive patients (DEP). SCZ and DEP met criteria for a diagnosis of schizophrenia or 
major depressive disorder according to the DSM-IV-TR and were recruited by senior psychiatrists 
from psychiatric departments of Central and South Paris area. COC met DSM-IV criteria for cocaine 
dependence and were recruited in the Cocaine Reference Center within Paul Brousse University 
Hospital, Villejuif (France). In this sample, SCZ were administered atypical antipsychotics in 
monotherapy, DEP were treated with Selective Serotonin Reuptake Inhibitors (SSRI) monotherapy 
(sertraline excluded), and COC were untreated. Urinary toxicology screening tests were carried out 
using benzoylecgonine (BE) dosage to ensure cocaine abstinence in COC patients. HC were recruited 
from the community through billboards in Paris area. 
Exclusion criteria were: age over 60, any substance related Axis I disorder in the past 6 months 
(except tobacco dependence for all participants and cocaine dependence for COC subgroup), 
treatment susceptible to interfere directly with DAT, electroconvulsive therapy treatment in the past 
six months, history of epileptic seizures, other psychiatric and/or neurological disorders or 
substantial brain damage, and contraindication to magnetic fields according to established safety 
criteria. Given the known action of psychoactive drugs on the DA system, semi-quantitative urinary 
multi-screens for the detection of cocaine, amphetamine, methamphetamine, cannabis, methadone, 
opiates, ecstasy, barbiturates, benzodiazepines, and tricyclic antidepressants (BMD: Biomedical 




During fMRI scanning, all participants completed the modified Monetary Incentive Delay task (MID-
task) reward paradigm (Figure 1), in which the main difference to the original version is the omission 
of loss trials (Knutson et al, 2000; Nees et al, 2012). 
MRI Acquisition 
Structural and functional MRI were acquired using a 1.5 Tesla whole-body system (Signa, General 
Electric, Milwaukee, Wisconsin). T1-weighted structural MRI scan was carried out with the following 
parameters: 3D Fourier transform spoiled-gradient-recalled acquisition with TR =12.5 ms, TE= 2.2 
ms, 124 contiguous slices, 256 × 256 view matrix, voxel size =0.9375 × 0.9375 × 1.3mm. 
For functional MRI, 66 randomized trials were presented and 290 volumes were acquired for a total 
duration of 11 min (Figure 1). Stimuli were presented through mirror glasses and an active matrix 
video projector. We acquired 36 slices in ascending order using a gradient-echo T2*-weighted 
sequence and the following image parameters: TR =2,400 ms, TE =30 ms, and an inplane matrix size 
of 64 × 64 pixels. Voxels size was 3.75 × 3.75 × 3 mm. 
fMRI Processing 
The fMRI data were processed using Statistical Parametric Mapping (SPM12, Wellcome Department 
of Imaging Neuroscience, University College London, London, UK). Images were corrected for slice 
timing, spatially realigned, warped onto the MNI space and smoothed using a 10mm FWHM 
Gaussian filter. First-level analysis of blood oxygen level-dependent (BOLD) signal change was 
performed by modeling anticipation and feedback as explanatory variables within a general linear 
model for each subject. We defined reward magnitudes of large, small and no win as subject specific 
variables of interest, and movement regressors were added to the design matrix. To focus on neural 
response during reward anticipation, we used the ‘anticipation of large win vs small win’ contrast in 
second-level analyses. 
PET Acquisition and Processing 
PET imaging was performed on a Siemens ECAT HRRT 3DPET scanner (CPS innovations Services, 
Knoxville, TN, USA) using [11C]PE2I tracer, a potent DAT radioligand that binds with high affinity (Ki: 
17 nM in vitro), specificity and selectivity to central DAT (Halldin et al, 2003). The radiotracer was 
prepared using a TRACERlab FX-C Pro synthesizer (Gems, Velisy, France). The PET acquisition started 
with the bolus injection of 300 MBq of [11C]PE2I and lasted 60 min (acquisition of 20 sequential 
frames from 1 to 5 min). Images were reconstructed using the ordinary Poisson-ordered subset 
expectation maximization (OPOSEM) algorithm with Point Spread Function (PSF) modeling. The voxel 
size was 1.2 × 1.2 × 1.2 mm. The injected radioactivity was 293.71±55.31MBq and the specific 
radioactivity was 32.13 ± 17.10 GBq/μmol. 
Head motion corrections were carried out post reconstruction using frame by frame co-registration 
of the PET dynamic series with a reference frame presenting a high[11C]PE2I uptake and a mutual 
information method within the BrainVISA/ Anatomist software (http://brainvisa.info). Thereafter, 
brain regions were determined by T1-MRI automatic parcellation and applied on dynamic 
coregistered PET images using the PNEURO tool of PMOD imaging software (Version 3.4, PMOD 
Technologies Ltd, Zürich, Switzerland), to process parametric binding potential images. Time–activity 
curves obtained from bilateral dorsal caudate and putamen nuclei as high-specific binding and crus1 
sub-region of the cerebellum as a reference tissue that display non-specific binding were exported to 
PMOD’s pixel-wise tool. Parametric maps of the regional [11C]PE2I non-displaceable binding 
potential (BPND) were generated using Gunn’s basis function method (Gunn et al, 1997), which is 
closely related to the simplified reference tissue model (SRTM) (Lammertsma and Hume, 1996). The 
suitability of specific [11C]PE2I binding quantification using a compartmental approach and the 
cerebellum as reference region has been confirmed by previous works (Seki et al, 2010). Spatial 
normalization was applied on the BPND maps using SPM8 with a ligand-specific [11C]PE2I template 
generated according to an MRI-aided procedure. The normalized BPND maps were smoothed using a 
10-mm FWHM Gaussian filter. The voxel size was 2 × 2 × 2mm. 
PET Statistical Analysis 
As previously described (Karila et al, 2016; Artiges et al, 2017), we used a mask for the PET statistical 
analysis, in order to include only main DA regions. It included basal ganglia, insula, amygdala, 
thalamus, midbrain, anterior cingulate gyrus, inferior frontal cortex, and temporal cortex 
(hippocampus, parahippocampal gyrus, superior temporal gyrus). 
To enable PET-fMRI correlations, we performed BPND values extraction from a one-sample t-test of 
PET images, using the MarsBaR toolbox implemented in SPM. Thus, individual averaged raw BPND 
values were extracted within specific anatomical regions of interest (ROIs) of the DA system. The 
ROIs included midbrain (substantia nigra (SN) and ventral tegmental area (VTA)), NAcc and dorsal 
striatum (dorsal caudate and dorsal putamen nuclei). As the spatial resolution of PET images does 




In order to examine the relationships between DAT availability and the reward system neural 
response, we performed a PET-fMRI multimodal analysis. Mean BPND values extracted from each 
previously defined ROI were included as covariate of interest in voxel-based correlation analyses 
over the fMRI contrast maps of reward anticipation ‘large win vs small win’. For each regional mean 
BPND, we performed a multiple regression analysis in SPM12. Age, clinical status, and tobacco use 
were included as confounding covariates, due to their potential effects on both DAT levels and 
functional activations. For these multimodal correlation analyses, height threshold was set at p<0.05 
family-wise error (FWE)-corrected and cluster significance (extent threshold) was set at 10 voxels. 
Multimodal correlation statistics were conducted within the mask of PET analysis, which includes 
mainly dopaminergic brain regions (Karila et al, 2016). This mask allowed the exclusion of premotor 
cortex activations occurring during reward anticipation periods preceding the motor response. As a 
control, we have tested the correlation between premotor cortex activations and DAT availability in 
the defined ROIs and no association was found (data not shown). 
Secondary Exploratory Analyses 
To further explore the results obtained from the PET–fMRI correlation, we ran a general linear 
model in a post hoc analysis using extracted BPND and activations raw data with JMP10 software 
(JMP, SAS Institute). Functional activation values were extracted from significant activated clusters 
of the fMRI contrast map ‘anticipation of large win vs small win’ using the MarsBaR toolbox in SPM. 
We included reward anticipation activations as independent variable and regional BPND values, age, 
tobacco use, and clinical subgroups as dependent variables of the model. We tested for the main 
effects of each dependent variable and for the subgroup*BPND interaction. Thereafter, we assessed 
the PET–fMRI correlation within each clinical subgroup separately in exploratory analyses, using a 
similar statistical model. 
RESULTS 
Participants’ Characteristics 
Subgroups of participants did not differ by age (mean = 36.52 ±8.00, χ2 =1.80, p= 0.61), body mass 
index (BMI) (mean= 25.86 ±4.06, χ2 =4.67, p =0.20) and daily tobacco consumption (mean =13.57± 
11.12, χ2= 3.05, p =0.38), as revealed by Kruskal–Wallis rank tests performed across the four clinical 
categories. 
Behavioral Results 
During the MID task, the participants displayed high rates of correct responses, on an average of 
86.50% mean success. ANOVA and post-hoc analyses of hit and miss rates under the three 
conditions (large, small, and no win) revealed a significant effect of incentive conditions (F= 7.69, p 
=0.0009), with lower performance in unrewarded trials compared to rewarded trials (large win vs no 
win: p =0.0008, small win vs no win: p =0.015). 
fMRI Results 
The reward anticipation contrast map ‘large win vs small win’ revealed specific activations in ventral 
parts of caudate and putamen nuclei, insula, anterior and mid cingulate cortices, inferior frontal 
cortex, premotor cortex, and supplementary motor area (Supplementary Table S1), as initially 
described by Knutson et al (2000, 2001a, 2001b) with the original MID task in healthy subjects. 
PET Results 
In the whole group, significant binding of [11C]PE2I was detected within the striatum (caudate and 
putamen), pallidum, insula, thalamus, hippocampus, and midbrain, as determined with the Montreal 
Neurological Institute (MNI) coordinates, from the local maxima of each region of the cluster 
(Supplementary Figure S2; Supplementary Table S2). 
PET–fMRI Correlation 
Across all participants, DAT availability in the midbrain correlated positively with anticipatory reward 
neural response in bilateral NAcc ([MNI coordinates x, y, z] : [ − 8, 16,− 10], t =8.61, pFWE= 0.0002; [8, 
16, − 12], t= 6.02, pFWE =0.015) and in the left inferior/orbital prefrontal cortex ([ − 24, 26, − 8], t= 
5.92, pFWE= 0.018); Figure 2. There was no significant correlation between BPND values in the dorsal 
striatum and reward-related activations. 
Secondary Exploratory Analyses 
A secondary analysis conducted on extracted fMRI contrast estimates confirmed that BPND values in 
the midbrain exert a significant influence on reward-related functional neural response in the 
ventral striatum cluster (likelihood ratio = 14.99, p<0.0001). Similarly, we found significant effects of 
age (positive effect, likelihood ratio = 25.79, p<0.0001), daily tobacco consumption (negative effect, 
likelihood ratio =9.98, p =0.0016), and subgroups (likelihood ratio = 29.93, p<0.0001) on fMRI 
contrast estimates, indicating a significant influence of these factors on NAcc reward-related neural 
response. Otherwise, there was no interaction between ‘subgroup’ and ‘midbrain BPND’ factors 
(likelihood ratio = 5.51, p= 0.1379), suggesting that the correlation between midbrain BPND values 
and the neural response to reward anticipation in the NAcc did not differ according to the clinical 
condition of the participants. When testing this correlation within each subgroup separately for 
exploratory analyses, we replicated our main result showing the influence of BPND values on fMRI 
contrast estimates (Figure 3) in HC (likelihood ratio =12.11, p =0.0005), COC (likelihood ratio = 11.40, 
p =0.0007), SCZ (likelihood ratio= 23.23, p<0.0001), and DEP (likelihood ratio= 6.20, p = 0.0128), 
despite the small sample sizes. 
DISCUSSION 
This is the first direct evidence of a relationship between DAT availability in the midbrain and BOLD 
activity within the NAcc and the left inferior/orbital prefrontal cortex during reward anticipation in 
healthy controls and psychiatric patients. 
This finding is in line with previous multimodal PET-fMRI studies that established a link between 
reward function and DA release in healthy humans. Using PET with [11C] raclopride or [18F]fallypride, 
and fMRI of reward anticipation, correlations between DA release in the NAcc and both midbrain 
and NAcc activations have been described (Schott et al, 2008; Buckholtz et al, 2010; Weiland et al, 
2016). Consistently with Schott et al (2008) report of a relationship between DA binding on D2 
receptors in the NAcc and functional activations in the midbrain, we report a correlation linking the 
DAT in the midbrain to the NAcc neural response, which associates the two main anatomically 
interconnected regions of the mesolimbic system. Moreover, the correlation between DAT 
availability in the midbrain and anticipatory reward response also included the left inferior/ orbital 
prefrontal cortex that receives a large amount of midbrain DA outputs from the mesocorticolimbic 
pathway, together with the NAcc and the anterior cingulate cortex (Haber and Behrens, 2014). In the 
other way, this region provides a large part of the cortical afferent projection to the NAcc (Haber and 
Behrens, 2014). These interconnections between the inferior/orbital prefrontal cortex, the NAcc and 
the midbrain are essential to the function of the reward system and underlie the consistency of our 
results. 
Surprisingly, the local correlation between DA and reward related activations within the NAcc 
reported in the previous studies was not replicated in our sample. This could be explained by the 
difference between the DA markers used, since our study explored DAT availability and previous 
works assessed DA receptors availability or DA release. However, when taking a more lenient extent 
threshold, we found a local positive correlation between DAT availability and anticipatory reward 
response within the left NAcc, ([ − 8, 18, − 10], t =6.17, pFWE=0.011). As the DAT represents a useful 
marker of the DA system integrity and function (McHugh and Buckley, 2015), and the NAcc is one of 
the main targets of DA neurons located in the midbrain, the correlations we found between DAT 
availability in the midbrain or in the NAcc and functional activity within the NAcc adds evidence for a 
modulatory role of DA in reward anticipation (Ikemoto, 2007). 
In addition, there is also indirect evidence of a relationship between DAT and reward processing, 
which emerged from studies that explored the links between dopaminergic gene variants and NAcc 
reward responsivity in healthy volunteers (Dreher et al, 2009; Camara et al, 2010; Greer et al, 2016), 
supporting the relevance of assessing DAT in a context of reward processing.  
Since the relationship between DA and reward is well established in animals (Schultz, 1997; Carelli 
and Wightman, 2004), we hypothesized that the DA function and the reward system neural activity 
remain strongly associated in humans with psychiatric disorders where dysfunctions of both systems 
were reported (Davis et al, 1991; Chau et al, 2004; Hommer et al, 2011; Fusar-Poli and Meyer-
Lindenberg, 2013), so that abnormal DA function should be associated to abnormal reward 
processing. Consistently with this hypothesis, we found no interaction between clinical subgroup 
and midbrain BPND on NAcc reward-related activations, suggesting that the relationship between 
DA function and reward anticipation does not differ according to the clinical subgroups. Remarkably, 
the DAT availability and reward anticipation measures vary similarly across the participants, so that 
the clinical subgroups with the lowest DAT levels display the lowest functional activations. Although 
observed in small samples of participants with various conditions, this original finding further 
supports the interest of a dimensional approach of the DA regulation as a modulator of the reward 
system.  
By merging different psychiatric patients and healthy controls, we obtained a large variability in PET 
and fMRI measures that can be described as a continuum through the clinical subgroups. In the 
context of the RDoC project, it has been proposed that a dimensional approach can be used across 
clinical categories to identify the pathophysiology of core dysfunctions found in mental illnesses 
(Insel et al, 2010). In the present study, despite the heterogeneity of psychiatric disorders examined, 
the relationship between DA and reward is conserved regardless of the condition of the participants. 
Besides, we replicated our main result in healthy controls and each patient subgroup separately. 
Although the interpretation of this exploratory analysis is limited by the number of participants in 
each subgroup, the results suggest that dopaminergic dysfunction is a common mechanism 
underlying the alterations of reward processing observed in patients with schizophrenia, depression, 
or addiction. Most importantly, these data demonstrate the relevance of studying the 
physiopathology of psychiatric disorders in a dimensional perspective. 
Some limitations should be highlighted. First, although the cohort size is in line with previous studies 
that combined PET and fMRI imaging (Schott et al, 2008; Weiland et al, 2014; Weiland et al, 2016), 
the small subgroup sizes do not enable robust intergroup comparisons and imply that subgroup 
results should be considered with caution. Second, as the effects of medication and groups cannot 
be disentangled in the statistical analyses, their putative impact need to be addressed in future 
studies. SCZ were treated with atypical antipsychotics that were shown to have no effect on the DAT 
(Lavalaye et al, 2000; Kim et al, 2004; Artiges et al, 2017) or on activation patterns to monetary 
reward in ventral striatum (Juckel et al, 2006; Walter et al, 2009; Nielsen et al, 2012). DEP were 
treated with SSRI. Although SRRIs do not bind tightly to DAT (Zhou et al, 2009), they were shown to 
induce an up-regulation of the DAT protein (Chen and Lawrence, 2003; Kugaya et al, 2003; Rominger 
et al, 2015). Thus, it cannot be excluded that SSRI treatment may have slightly influenced DAT 
quantification in depressed patients. Regarding reward processing, whether SSRI treatment 
influences functional activity during reward tasks in patients with depression remains unclear. In 
healthy controls, SSRI treatment was shown to reduce the responsiveness to reward in fMRI 
(Macoveanu et al, 2014; Graf et al, 2016). However, Stoy et al (2012) evidenced a hyporeactivity to 
reward in unmedicated depressed patients, which is normalized after successful SSRI treatment. 
Overall, the potential impacts of medications on PET and fMRI measures could be considered as a 
limitation of the study. Besides, although the [11C]PE2I binds with high affinity to the DAT and is 
about 120–145 × more potent that DA itself (Reith et al, 1996), an effect of endogenous DA on DAT 
binding cannot be excluded. Another limitation arises from the differences between the behavioral 
and clinical features assessed in the studies that form our database, thus precluding dimensional 
correlations between imaging data and psycho-behavioral measures. 
The combined use of PET and fMRI allows the assessment of DA and reward neural networks from 
molecular to functional levels. The present results demonstrate for the first time that DAT 
availability in the midbrain, which contains the cell bodies of dopaminergic neurons, correlates with 
BOLD activity during reward anticipation in the NAcc, the main DA target within the mesolimbic 
pathway. This relationship between DA and reward systems transcends diagnostic categories in 
psychiatric patients, which highlights the interest of studying such systems in patients with a 
dimensional approach. The use of multimodal and multiscale assessments in a dimensional 
perspective could give an overall view of molecular, structural and functional alterations that 
underlie the pathophysiology of psychiatric disorders in future research and could lead to the 
development of new treatment strategies thereafter. 
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Figure 1 Modified Monetary Incentive Delay task participants have to respond as quickly as possible 
with left or right index finger to hit a target (white square) that appears for a short time on the left 
or right side of the screen. When subjects hit the target in time on the appropriate side, they score 
points. A preceding clue provides information on the points to be won. A triangle indicates no 
points, a circle with one line, two points, and a circle with three lines, ten points. For each condition 
(no win, small win, and big win), 22 trials were presented in equal proportion for each target side. A 













Figure 2 Correlation between midbrain dopamine transporter (DAT) availability and anticipatory 
reward activations. (a) Slice views of [11C]PE2I nondisplaceable binding potential (BPND) maps with 
delineated midbrain region of interest where BPND values were extracted (upper), and fMRI 
contrast map of reward anticipation ‘large win vs small win’ (lower). (b) Slice view of the correlated 
cluster (388 voxels mainly including nucleus accumbens) overlaid onto a MRI template. For 
presentation purpose, we used a significance threshold set at 0.001 uncorrected for voxel level and 
an extent threshold set at 0.05 familywise error (FWE)-corrected for multiple comparisons. (c) Plot of 














Figure 3 PET–fMRI correlation within each subgroup. Correlation graph derived from general linear 
model analyses conducted within each subgroup and including functional MRI contrast ‘anticipation 
of large win vs small win’ estimates in the nucleus accumbens as exploratory variable and midbrain 
[11C]PE2I non-displaceable binding potential (BPND) as explanatory variable. 
 
 
 
 
 
 
 
